What is Talosix?
Talosix operates at the intersection of artificial intelligence and clinical research, offering a sophisticated platform designed to streamline the complexities of patient recruitment and study management. The company provides a comprehensive suite of tools that assist sponsors, contract research organizations (CROs), and healthcare providers in optimizing the lifecycle of clinical trials. Through automated patient screening, robust data collection, and real-time compliance support, Talosix addresses the persistent inefficiencies in medical research. By utilizing AI-driven insights, the platform facilitates more precise patient matching and enhances the overall quality of data reporting, ultimately accelerating the time-to-market for life-saving therapies and medical innovations.
How much funding has Talosix raised?
Talosix has raised a total of $235K across 1 funding round:
Debt
$235K
Debt (2021): $235K with participation from PPP
Key Investors in Talosix
PPP
Public-Private Partnership
What's next for Talosix?
With this late-stage capital, Talosix is well-positioned to scale its operations and deepen its market penetration within the global clinical research ecosystem. The strategic focus will likely shift toward expanding its AI capabilities to handle increasingly complex datasets and enhancing its interoperability with existing hospital and CRO information systems. As the demand for decentralized and patient-centric clinical trials grows, Talosix is poised to capitalize on its technological foundation to become an indispensable partner for organizations seeking to improve trial outcomes and operational efficiency. Future growth will likely involve strategic partnerships with major pharmaceutical entities to integrate their recruitment and management tools into broader drug development pipelines.
See full Talosix company page
